Jenny Strasburg is a reporter in London, where she writes for The Wall Street Journal about oil and gas, climate, the ...

James Willhite was an editor with The Wall Street Journal's money & investing team based in London.

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...

If generative AI could contribute in the slightest to such discoveries—as has been promised since the start of the AI ...

The United States is already falling behind China in countless technological advancements, thanks to several Biden-era policies.

Novavax's COVID-19 vaccine could soon receive full approval from the U.S. Food and Drug Administration (FDA), the company ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

BofA lowered the firm’s price target on Moderna (MRNA) to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm’s ...

CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA ...

Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement ...